Seems very promising and better than CF101.
Here is what I found:
"~50-70% of the patients using fumaderm have achieved PASI 75 improvement within four months of treatment and without any apparent long-term side effect or increased risk of infection or malignancy".
you meant future profit or cut loss? I will be luck to break even at price 45 cents on average. A profit is hard to get.
I like both, canf is riskier but has a greater potential for share rise, xnpt is less risk and offer great investment for the long run, but the share price has already tripled from the low.
I think you meant canf. Coinsidently, I own both of them. I think both companies will do great in the short and long run. 829 was the high hope for xnpt, but now I think the street is more enthusiasm on gabapentin enacarbil. The drug is currently doing very well on the fda approved indication, and is potentially huge on alcoholics.
Comparing with other similar companies including arna, smcp, and supn, xnpt could be easily double to reach the same levels of valuation.
Teva has file with FDA a new ANAD for a generic version of Qsymia. Considering Teva has just signed a new contract with ipci on an unnamed drug, it is possible that ipci has made the extended release of Qsymia for Teva.